October 15, 2024 02:08 PM EDT
Pharma

J&J’s medtech slump con­tin­ues, im­prove­ments not ex­pect­ed un­til 2025

Max Bayer

Pharma Reporter

John­son & John­son beat in­vestors’ ex­pec­ta­tions de­spite its medtech unit un­der­per­form­ing, with ex­ecs point­ing to the Asia-Pa­cif­ic re­gion as a con­tin­ued source of strug­gle. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times